Alation introduced a new AI governance offering.

This title highlights a critical challenge I see across Europe: companies rush into AI without the necessary controls. Alation's move indicates that serious tools for AI governance are emerging, not just hype. For a pharma or legal firm, this means you must define how AI is used, who accesses what data, and how decisions are made. The EU AI Act countdown is real; you need an adult in the room for governed execution, especially with client data.